Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St. Jude AML97 Trial
暂无分享,去创建一个
Dario Campana | Jeffrey E. Rubnitz | James R. Downing | Kristine R. Crews | Ching-Hon Pui | Susana C. Raimondi | Stanley Pounds | Raul C. Ribeiro | J. Downing | S. Raimondi | D. Campana | C. Pui | R. Ribeiro | V. Gandhi | J. Rubnitz | S. Pounds | K. Crews | B. Razzouk | Shengping Yang | Varsha V. Gandhi | Bassem I. Razzouk | Sheng-ling Yang
[1] C. Pui,et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia , 2008, Cancer.
[2] S. Feig,et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. , 2008, Blood.
[3] T. Alonzo,et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. , 2007, Blood.
[4] D. Reinhardt,et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] F. Behm,et al. children with AML in remission : Pediatric Oncology Group Study 9421 Randomized use of cyclosporin A ( CsA ) to modulate P-glycoprotein in , 2005 .
[6] U. Creutzig,et al. Pediatric acute myeloid leukemia: international progress and future directions , 2005, Leukemia.
[7] R. Hills,et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials , 2005, Leukemia.
[8] D. Reinhardt,et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Pui,et al. Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. , 2004, Leukemia research.
[10] D. Reinhardt,et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93 , 2004, Leukemia.
[11] J. Downing,et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia , 2003, British journal of haematology.
[12] G. Gustafsson,et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO‐AML trials , 2003, British journal of haematology.
[13] Deo Kumar Srivastava,et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Raimondi,et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] T. Robak,et al. Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia , 2000, Leukemia & lymphoma.
[16] R. Gray,et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial , 1998 .
[17] R. Gray,et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. , 1998, British journal of haematology.
[18] E. Estey,et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. , 1996, Leukemia.
[19] E. Estey,et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. , 1996, Blood.
[20] R. Krance,et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. , 1994, Blood.
[21] M. Story,et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine , 1993 .
[22] M. Story,et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. , 1993, Blood.
[23] M. Schell,et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Schell,et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Carson,et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. , 1990, The Journal of clinical investigation.